Biocon’s Avastin Biosimilar To Put The Heat On Competition?
Executive Summary
Biocon has launched its biosimilar Avastin in India, intensifying competition on the market. In addition to its ‘affordable’ price, Biocon’s biosimilar Avastin also comes with a novel temperature-sensitive packaging, which it sees as a key differentiator. Roche meanwhile underscored the need to be “very careful” while making packaging changes with biologics.
You may also be interested in...
Can Dr Reddy’s Carve Into Crowded Indian Avastin Biosimilar Market?
Dr Reddy’s debuts biosimilar bevacizumab in India but can the significant price differential for one strength of the product help it gnaw into a competitive market?
Can Dr Reddy’s Carve Into Crowded Indian Avastin Biosimilar Market?
Dr Reddy’s debuts biosimilar bevacizumab in India but can the significant price differential for one strength of the product help it gnaw into a competitive market?
Roche To Set Right Avastin Post-Marketing Surveillance Delay In India
Roche is working towards implementing PMS studies for Avastin (bevacizumab) and ensuring that a suspension of marketing authorization for the product in first line ovarian cancer is lifted in India.